Cubist Systematic Strategies, LLC Tg Therapeutics, Inc. Call Options Transaction History

Cubist Systematic Strategies, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $5,163 - $7,584	300 Added 2.01%	15,200 $355,000
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $484,848 - $698,516	-36,400 Reduced 70.96%	14,900 $265,000
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $470,022 - $768,930	-36,100 Reduced 41.3%	51,300 $780,000
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $96,192 - $270,864	14,400 Added 19.73%	87,400 $1.49 Million
Q3 2023 Nov 14, 2023	SELL	$8.36 - $26.5 $836 - $2,650	-100 Reduced 0.14%	73,000 $610,000
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $1.13 Million - $2.56 Million	73,100 New	73,100 $1.82 Million

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.